Quick Answer
Prelude Therapeutics Inc reported Diluted EPS of $1.29 per share (loss) for fiscal year 2025.
Prelude Therapeutics Inc Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.29 | +23.2% |
| 2024 | -$1.68 | +16.8% |
| 2023 | -$2.02 | +17.2% |
| 2022 | -$2.44 | -0.4% |
| 2021 | -$2.43 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.26 | +39.5% | +36.6% |
| June 30, 2025 | -$0.41 | +10.9% | +2.4% |
| March 31, 2025 | -$0.42 | +0.0% | +2.3% |
| September 30, 2024 | -$0.43 | +4.4% | +6.5% |
| June 30, 2024 | -$0.46 | +14.8% | -9.5% |
| March 31, 2024 | -$0.42 | +27.6% | +6.7% |
| September 30, 2023 | -$0.45 | +28.6% | +16.7% |
| June 30, 2023 | -$0.54 | +6.9% | +6.9% |
- Prelude Therapeutics Inc showed an increase of +23.2% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Prelude Therapeutics Inc’s diluted eps has grown by 46.9% (from $2.43 per share (loss) to $1.29 per share (loss)).
- The most recent figure is from Prelude Therapeutics Inc’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: